i-manager Publications

Pediatric Leukemia: A Clinical and Therapeutic Perspective on Challenges and Progress

Remya S. B.*

The Dale View College of Pharmacy and Research Centre, Kerala, India.

Periodicity:July - December'2025
DOI : https://doi.org/10.26634/djcp.2.2.22489

Abstract

Leukemia is a malignancy affecting the blood-forming tissues, including the bone marrow, and represents the most frequently diagnosed cancer in the pediatric population, accounting for over one-quarter of childhood cancer cases. The disease disrupts normal white blood cell production, leading to immune suppression and increased vulnerability to infections. Impaired immunity frequently necessitates intensive management of both opportunistic infections and the malignancy itself. This review examines the complete clinical spectrum of pediatric leukemia, encompassing diagnostic methods, disease progression, physiological alterations, and therapeutic strategies. Advances over recent decades, supported by large-scale clinical trials and cohort analyses, have introduced novel treatment agents that improve survival outcomes while reducing treatment-related complications. Overall, the review highlights contemporary best practices in managing childhood leukemia.

Keywords

Leukemia, Airborne Infections, Microorganisms, Cancer, Blood Cells.

How to Cite this Article?

Remya, S. B. (2025). Pediatric Leukemia: A Clinical and Therapeutic Perspective on Challenges and Progress. Dale View's Journal of Clinical Pharmacology and Pharmacotherapeutics, 2(2), 33-45. https://doi.org/10.26634/djcp.2.2.22489

References

[1]. American Cancer Society. (2008). Cancer Facts & Figures 2008. American Cancer Society.

[2]. Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., Thiele, J., & Vardiman, J. W. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International agency for research on cancer.

[3]. Elbedewy, T. A., & Elashtokhy, H. E. (2016). The utility and applicability of chronic myeloid leukemia scoring systems for predicting the prognosis of Egyptian patients on Imatinib: retrospective study. Journal of Leukemia, 4(210), 1-9.

[4]. Gale, K. B., Ford, A. M., Repp, R., Borkhardt, A., Keller, C., Eden, O. B., & Greaves, M. F. (1997). Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proceedings of the National Academy of Sciences, 94(25), 13950-13954.

[5]. Greaves, M. F. (1997). Aetiology of acute leukaemia. The Lancet, 349(9048), 344-349.

[6]. Gurney, J. G., Severson, R. K., Davis, S., & Robison, L. L. (1995). Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer, 75(8), 2186-2195.

[7]. Haggag, R., Hussein, O., El Moaty, H. A., Omran, A., & Ebian, H. (2016). Study of plasma endostatin level in patients with acute myeloid leukemia. Advances in Oncology Research and Treatments, 1(107), 2.

[8]. Hasle, H., Clemmensen, I. H., & Mikkelsen, M. (2000). Risks of leukaemia and solid tumours in individuals with Down's syndrome. The Lancet, 355(9199), 165-169.

[9]. Horwitz, M. (1997). The genetics of familial leukemia. Leukemia, 11(8), 1347-1359.

[10]. Kinlen, L. (2004). Infections and immune factors in cancer: the role of epidemiology. Oncogene, 23(38), 6341-6348.

[11]. Man, L. M., Morris, A. L., & Keng, M. (2017). New therapeutic strategies in acute lymphocytic leukemia. Current Hematologic Malignancy Reports, 12(3), 197-206.

[12]. Pabst, T., Kortz, L., Fiedler, G. M., Ceglarek, U., Idle, J. R., & Beyoğlu, D. (2017). The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. BBA Clinical, 7, 105-114.

[13]. SEER Program (National Cancer Institute (US)). (1999). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995 (No. 99). National Cancer Institute.

[14]. Sharma, R. K., Puri, V., Mutreja, D., Kumar, S., Chauhan, P., Purohit, A., & Saxena, R. (2015). Applicability of a single 5 color cytoplasmic markers tube as primary panel in routine immunophenotyping of acute leukemia. Journal of Blood Disorders & Transfusion, 6(309), 2.

[15]. Shivakumar, R., Tan, W., Wilding, G. E., Wang, E. S., & Wetzler, M. (2008). Biologic features and treatment outcome of secondary acute lymphoblastic leukemia—a review of 101 cases. Annals of Oncology, 19(9), 1634-1638.

[16]. Spector, L. G., Charbonneau, B., & Robison, L. L. (2010). Epidemiology and Etiology. Childhood Leukemias.

[17]. Tanyildiz, H. G., Malbora, B., Yesil, S., Tekgunduz, S. A., & Candir, M. O. (2014). Vitamin B12 deficiency mimicking acute leukemia in a child. Journal of Clinical Case Reports, 4(10), 430.

[18]. Taub, J. W., Konrad, M. A., Ge, Y., Naber, J. M., Scott, J. S., Matherly, L. H., & Ravindranath, Y. (2002). High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood, the Journal of the American Society of Hematology, 99(8), 2992-2996.

[19]. Zhu, H. H., Liu, Y. R., & Qin, Y. Z. (2016). CD34-negative is highly associated with T (15; 17), T (V; 11q23) and the NPM1-mutation subtypes in 343 newly diagnosed patients with acute myeloid leukemia. Chemo Open Access, 5(2), 200.

If you have access to this article please login to view the article or kindly login to purchase the article

Single Article

	North Americas,UK, Middle East,Europe		India	Rest of world
	USD	EUR	INR	USD-ROW
Pdf	300
Online	300
Pdf & Online	500

ADD TO CART

Options for accessing this content:

If you would like institutional access to this content, please recommend the title to your librarian.
If you already have i-manager's user account: Login above and proceed to purchase the article.
New Users: Please register, then proceed to purchase the article.